Anti-Ganglioside GD2 [ME361] Antibody

This mouse IgG monoclonal antibody recognizes human ganglioside GD2.


  • Specific for human ganglioside GD2
  • Has low affinity for GD3 a surface marker present on several neuroectodermal tumors including melanoma
  • ME 36.1 has been found to inhibit tumor growth at the inoculation site as well as metastatic spread to lymph nodes and lungs in preclinical studies
  • Suitable for FACS, Immunohistochemistry and Binding Assay applications

Ganglioside GD2, is a sialic acid-containing glycosphingolipid involved in cell attachment to the extracellular matrix. GD2 is overexpressed on neuroblastoma, retinoblastoma, melanoma, small cell lung cancer, brain tumors, osteosarcoma, rhabdomyosarcoma tissues. GD2 localizes to the cell surface. GD2 has been shown to enhance tumor proliferation and invasiveness in osteosarcoma and small cell lung cancer cells.

From the laboratory of Meenhard Herlyn, DVM, DSc, The Wistar Institute.

The Investigator's Annexe Part of The Investigator's Annexe program.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
Anti-Ganglioside GD2 [ME361] Antibody
100ug In stock
Regular Price:$375.00
On Sale:

Product Type: Antibody
Antigen: Ganglioside GD2
Accession ID: CAS Number 65988-71-8; bDGalpNAc(1-4)[aNeu5Ac(2-8)aNeu5Ac(2-3)]bDGalp(1-4)bDGlcp(1-1)Cer
Isotype: IgG2a/kappa
Clonality: Monoclonal
Clone Name: ME361 / ME36.1
Reactivity: Human
Species Immunized: Mouse
Purification Method: Protein G
Buffer: 0.1M Sodium Phosphate, pH 7.4, 0.15M NaCl, 0.05% (w/v) Sodium Azide
Tested Applications: FACS (1:50), IHC (1:50), Binding assays (1:50)
Storage: -20C
Shipped: Cold packs

From the laboratory of Meenhard Herlyn, DVM, DSc, The Wistar Institute.
  1. Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014 Jan 21;588(2):288-97.
  2. Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, Elder DE, Bondi E, Guerry D, Nowell P, Clark WH, et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res. 1985 Nov;45(11 Pt 2):5670-6.
  3. Iliopoulos, D; Ernst, C; Steplewski, Z; Jambrosic, J A; Rodeck, U; Herlyn, M; Clark, W H; Koprowski, H; Herlyn, D. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides.J Natl Cancer Inst. 1989 03 15;81(6):440-4
  4. Pichla, S L; Murali, R; Burnett, R M. The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside.J Struct Biol. 1997 06;119(1):6-16
  5. Pichla, S L; Murali, R; Burnett, R M. Preliminary crystallographic data for an Fab to the melanoma-associated GD2 ganglioside, and the purification of a soluble form of this antigen.Acta Crystallogr D Biol Crystallogr. 1995 01 01;51(Pt 1):124-6
  6. Kieber-Emmons, Thomas; Monzavi-Karbassi, Bejatohlah; Pashov, Anastas; Saha, Somdutta; Murali, Ramachandran; Kohler, Heinz. The promise of the anti-idiotype concept.Front Oncol. 2012;2:196
  7. Vázquez, Ana M H; Rodrèguez-Zhurbenko, Nely; López, Ana M V. Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.Front Oncol. 2012;2:170
  8. Agostino, Mark; Yuriev, Elizabeth; Ramsland, Paul A. Antibody recognition of cancer-related gangliosides and their mimics investigated using in silico site mapping.PLoS One. 2012;7(4):e35457
  9. Ahmed, Mahiuddin; Goldgur, Yehuda; Hu, Jian; Guo, Hong-Fen; Cheung, Nai-Kong V. In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors.PLoS One. 2013;8(5):e63359
  10. Cheung, Nai-Kong V; Guo, Hongfen; Hu, Jian; Tassev, Dimiter V; Cheung, Irene Y. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.Oncoimmunology. 2012 07 01;1(4):477-486
  11. Bernhard, H; Karbach, J; Strittmatter, W; Meyer Zum Büschenfelde, K H; Knuth, A. Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3.Int J Cancer. 1993 09 30;55(3):465-70
  12. Ruf, Peter; Schäfer, Beatrix; Eissler, Nina; Mocikat, Ralph; Hess, Juergen; Plöscher, Matthias; Wosch, Susanne; Suckstorff, Ivonne; Zehetmeier, Christine; Lindhofer, Horst. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.J Transl Med. 2012 11 07;10:219
  13. Kieber-Emmons, Thomas; Saha, Somdutta; Pashov, Anastas; Monzavi-Karbassi, Behjatolah; Murali, Ramachandran. Carbohydrate-mimetic peptides for pan anti-tumor responses.Front Immunol. 2014;5:308
  14. Wondimu, Assefa; Zhang, Tianqian; Kieber-Emmons, Thomas; Gimotty, Phyllis; Sproesser, Katrin; Somasundaram, Rajasekharan; Ferrone, Soldano; Tsao, Chun-Yen; Herlyn, Dorothee. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.Cancer Immunol Immunother. 2008 07;57(7):1079-89
  15. Dobrenkov, Konstantin; Cheung, Nai-Kong V. GD2-targeted immunotherapy and radioimmunotherapy.Semin Oncol. 2014 10;41(5):589-612
  16. Díaz-Zaragoza, Mariana; Hernández-Ávila, Ricardo; Viedma-Rodríguez, Rubí; Arenas-Aranda, Diego; Ostoa-Saloma, Pedro. Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review).Oncol Rep. 2015 09;34(3):1106-14
  17. Somasundaram, Rajasekharan; Caputo, Laura; Guerry, DuPont; Herlyn, Dorothee. CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma.J Transl Med. 2005 11 10;3:41
  18. Doronin, Igor I; Vishnyakova, Polina A; Kholodenko, Irina V; Ponomarev, Eugene D; Ryazantsev, Dmitry Y; Molotkovskaya, Irina M; Kholodenko, Roman V. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.BMC Cancer. 2014 04 28;14:295
  19. Cheng, Ming; Ahmed, Mahiuddin; Xu, Hong; Cheung, Nai-Kong V. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.Int J Cancer. 2015 01 15;136(2):476-86
  20. Deppisch, Nina; Ruf, Peter; Eißler, Nina; Lindhofer, Horst; Mocikat, Ralph. Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.Oncotarget. 2017 01 17;8(3):4520-4529
  21. Airoldi, I; Lualdi, S; Bruno, S; Raffaghello, L; Occhino, M; Gambini, C; Pistoia, V; Corrias, M V. Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L.Br J Cancer. 2003 05 19;88(10):1527-36

If you publish research with this product, please let us know so we can cite your paper.